Mycobacterium tuberculosis evasion of CD4+ T cells in vivo
Mycobacterium tuberculosis evasion of CD4+ T cells in vivo
批准号:
8414848
负责人:
Joel D. Ernst
金额:
$36.99万
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
已结题
起止时间:
2010-01-15 至 2015-12-31
关键词:
AcuteAdjuvantAntigen PresentationAntigen-Presenting CellsAntigensBacteriaBone MarrowBypassCD4 Positive T LymphocytesCellsChronicCommunicable DiseasesComplexDataDendritic CellsDetectionDevelopmentDiseaseDown-RegulationDrug Resistant TuberculosisDrug resistanceExhibitsExtreme drug resistant tuberculosisFrequenciesFutureGenesGranulomaHIVHistocompatibility Antigens Class IIHumanImageryImmuneImmune responseImmunityIn VitroIndividualInfectionInfection ControlLungMHC Class II GenesMethodsMinorityMonoclonal AntibodiesMultidrug-Resistant TuberculosisMusMycobacterium tuberculosisMycobacterium tuberculosis antigen 85BMyelogenousPeptide/MHC ComplexPharmaceutical PreparationsPhasePopulationPublic HealthPublicationsReaction TimeReagentRecombinantsRecording of previous eventsReportingResistanceSiteStagingSystemT cell responseT-Cell ReceptorT-LymphocyteTestingTransgenic OrganismsTuberculosisTuberculosis VaccinesVaccinesadaptive immunityattenuationbaseimmune clearanceimprovedin vivoindexinginsightmacrophagemouse modelnovelnovel strategiespandemic diseasepreventpublic health relevanceresearch studysuccesstool
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): The greatest barrier to development of efficacious vaccines against tuberculosis is the ability of Mycobacterium tuberculosis to persist and to cause progressive infection despite development of an adaptive immune response. While partially-efficacious vaccines may result from optimal selection of antigens, adjuvants, and delivery systems, major progress against tuberculosis will require novel approaches to enhancing resistance, based on overcoming or bypassing the mechanisms used by M. tuberculosis to evade adaptive immune responses. To identify and characterize those mechanisms, we have developed novel tools for use in a mouse model of immunity to M. tuberculosis to discover and characterize mechanisms that limit the efficacy of the adaptive immune response to M. tuberculosis. We have developed a system using a monoclonal antibody that recognizes a specific peptide:MHC II complex and several recombinant strains of M. tuberculosis, to test the hypothesis that M. tuberculosis inhibits MHC II antigen presentation in vivo, and to test the hypothesis that M. tuberculosis transfers antigens to uninfected cells as an immune evasion strategy. We have also developed a system using CD4+ T cells from a unique line of mice with a transgenic T cell antigen receptor specific for M. tuberculosis Ag85B, and have discovered that downregulation of the gene encoding Ag85B during the chronic stage of M. tuberculosis infection is accompanied by diminished in vivo CD4+ T cell responses to Ag85B. Taken together, these results suggest that M. tuberculosis may modulate expression of antigen genes as a means of avoiding recognition and elimination by CD4+ effector T cells. We also developed a method for visualization and localization of M. tuberculosis-infected cells and CD4+ T cells in the lungs, and have found that a minority of M. tuberculosis-infected cells in the lungs are in direct contact with CD4+ T cells, which supports the hypothesis that CD4+ T cells recognize M. tuberculosis-infected cells poorly at the site of infection. In this application, we propose experiments to test the general hypothesis that interactions between M. tuberculosis-infected cells and antigen-specific CD4+ T cells in the lungs are defective, and that this contributes to persistence of the infection. We will test the specific hypothesis that defective interactions between M. tuberculosis-infected cells and CD4+ T cells during chronic infection are due to a combination of: 1) M. tuberculosis inhibition of antigen presentation by infected cells; 2) decreased expression of M. tuberculosis antigens during the chronic stage of infection; and 3) transfer of M. tuberculosis antigens from infected cells to neighboring uninfected cells in granulomas, allowing uninfected cells to act as decoys to activate T cells at a distance from infected cells. Our proposed studies will provide unprecedented insight into the mechanisms used by M. tuberculosis to evade elimination by the mammalian adaptive immune response, and will guide future efforts to develop the means to increase human resistance to tuberculosis.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Functionally distinct human CD4 T cell responses to novel evolutionarily selected M. tuberculosis antigens
-
批准号:10735075
-
项目类别:
-
资助金额:$85.51万
-
财政年份:2023
-
负责人:Joel D. Ernst
-
依托单位:
Functional dynamics of TB granuloma architecture
-
批准号:10593978
-
项目类别:
-
资助金额:$61.57万
-
财政年份:2022
-
负责人:Joel D. Ernst
-
依托单位:
Functional dynamics of TB granuloma architecture
-
批准号:10358264
-
项目类别:
-
资助金额:$62.38万
-
财政年份:2022
-
负责人:Joel D. Ernst
-
依托单位:
Live Imaging of Immunity to M. tuberculosis
-
批准号:10326395
-
项目类别:
-
资助金额:$10.1万
-
财政年份:2021
-
负责人:Joel D. Ernst
-
依托单位:
Host genetic diversity, mononuclear phagocytes, and outcomes of TB
-
批准号:10005738
-
项目类别:
-
资助金额:$28.23万
-
财政年份:2020
-
负责人:Joel D. Ernst
-
依托单位:
Host genetic diversity, mononuclear phagocytes, and outcomes of TB
-
批准号:10194362
-
项目类别:
-
资助金额:$16.15万
-
财政年份:2020
-
负责人:Joel D. Ernst
-
依托单位:
Antigen export in M. tuberculosis evasion of CD4 T cells
-
批准号:9318402
-
项目类别:
-
资助金额:$72.01万
-
财政年份:2016
-
负责人:Joel D. Ernst
-
依托单位:
Epitope-specific T cell activation to complement TB immunity and vaccine efficacy
-
批准号:8867688
-
项目类别:
-
资助金额:$50.25万
-
财政年份:2014
-
负责人:Joel D. Ernst
-
依托单位:
Initiation of the Immune Response to M. tuberculosis
-
批准号:8678398
-
项目类别:
-
资助金额:$50.59万
-
财政年份:2014
-
负责人:Joel D. Ernst
-
依托单位:
Mycobacterium tuberculosis evasion of CD4+ T cells in vivo
-
批准号:8678383
-
项目类别:
-
资助金额:$36.42万
-
财政年份:2013
-
负责人:Joel D. Ernst
-
依托单位:
Training Program in Immunology and Inflammation
-
批准号:8495260
-
项目类别:
-
资助金额:$19.63万
-
财政年份:2012
-
负责人:Joel D. Ernst
-
依托单位:
Training Program in Immunology and Inflammation
-
批准号:8663183
-
项目类别:
-
资助金额:$19.95万
-
财政年份:2012
-
负责人:Joel D. Ernst
-
依托单位:
Mycobacterium tuberculosis evasion of CD4+ T cells in vivo
-
批准号:8602804
-
项目类别:
-
资助金额:$39.35万
-
财政年份:2010
-
负责人:Joel D. Ernst
-
依托单位:
Mycobacterium tuberculosis evasion of CD4+ T cells in vivo
-
批准号:7800614
-
项目类别:
-
资助金额:$41.35万
-
财政年份:2010
-
负责人:Joel D. Ernst
-
依托单位:
Mycobacterium tuberculosis antigen diversity
-
批准号:8084140
-
项目类别:
-
资助金额:$67.45万
-
财政年份:2010
-
负责人:Joel D. Ernst
-
依托单位:
Mycobacterium tuberculosis evasion of CD4+ T cells in vivo
-
批准号:8011522
-
项目类别:
-
资助金额:$40.5万
-
财政年份:2010
-
负责人:Joel D. Ernst
-
依托单位:
Mycobacterium tuberculosis evasion of CD4+ T cells in vivo
-
批准号:8207965
-
项目类别:
-
资助金额:$39.35万
-
财政年份:2010
-
负责人:Joel D. Ernst
-
依托单位:
Mycobacterium tuberculosis antigen diversity
-
批准号:8280454
-
项目类别:
-
资助金额:$64.76万
-
财政年份:2010
-
负责人:Joel D. Ernst
-
依托单位:
Mycobacterium tuberculosis antigen diversity
-
批准号:8476981
-
项目类别:
-
资助金额:$59.56万
-
财政年份:2010
-
负责人:Joel D. Ernst
-
依托单位:
Mycobacterium tuberculosis antigen diversity
-
批准号:7993393
-
项目类别:
-
资助金额:$66.46万
-
财政年份:2010
-
负责人:Joel D. Ernst
-
依托单位:
海外基金